Back

Vessel Organoids Reveal FOXF1 Variant-Specific Regulation of Mesoderm and Capillary Development

Pek, N. M.; Thorner, K.; Guo, M.; Dennison, H.; Rajaguru, T.; Stan, G.; Kishimoto, K.; Rottier, R.; Kotton, D. N.; Zorn, A. M.; Gu, M.

2026-07-14 developmental biology
10.64898/2026.07.12.737936 bioRxiv
Show abstract

How allelic variants in lineage-regulating transcription factors drive diverging human developmental outcomes remains poorly understood. This is partly due to the lack of human model systems. Here, we used vessel organoids from human induced pluripotent stem cells (hiPSCs) to resolve variant-specific functions of Forkhead Box F1 (FOXF1), a critical regulator of mesoderm and vascular development. Using three patient-derived hiPSC lines harboring unique FOXF1 variants, we show that heterozygous variants cause capillary maldevelopment of varying severity. Single-nucleus multiomic analysis revealed variant-specific mechanisms - a severe variant impairs differentiation of nascent mesoderm to lateral plate mesoderm and disrupts vascular progenitor specification, while moderate variants permit mesoderm differentiation but rewire vascular progenitor states and function. Restoration of wild-type FOXF1 via lipid nanoparticle-mediated mRNA delivery rescued capillary formation in a variant- and developmental-stage-dependent manner. Together, these findings demonstrate that different variants disrupt stage-specific FOXF1 functions in human mesoderm-to-vascular development, underscoring the importance of variant-specific therapeutic strategies. HIGHLIGHTS O_LIHuman vessel organoids reveal variant-specific roles of FOXF1 in mesoderm patterning and capillary development. C_LIO_LISevere FOXF1 variant c.253T>A (p.F85I) impairs nascent mesoderm-to-lateral plate mesoderm differentiation and disrupts vascular progenitor specification. C_LIO_LI Moderate FOXF1 variants differentially rewire endothelial and mural progenitor cell states and function. C_LIO_LILipid nanoparticle-mediated FOXF1 mRNA delivery rescues capillary formation in a variant- and developmental-stage-dependent manner. C_LI

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cell Stem Cell
62 papers in training set
Top 0.1%
18.0%
2
Nature Communications
5641 papers in training set
Top 12%
14.7%
3
Developmental Cell
196 papers in training set
Top 0.4%
7.1%
4
Arteriosclerosis, Thrombosis, and Vascular Biology
71 papers in training set
Top 0.4%
5.3%
5
Cell Reports
1498 papers in training set
Top 9%
4.2%
6
Circulation Research
47 papers in training set
Top 0.4%
4.2%
50% of probability mass above
7
Science Advances
1243 papers in training set
Top 13%
2.7%
8
Circulation
74 papers in training set
Top 1%
2.7%
9
Cell
431 papers in training set
Top 4%
2.4%
10
Stem Cell Reports
130 papers in training set
Top 0.9%
2.3%
11
Cardiovascular Research
37 papers in training set
Top 0.6%
2.1%
12
EMBO Molecular Medicine
95 papers in training set
Top 0.7%
2.1%
13
Advanced Science
286 papers in training set
Top 4%
1.9%
14
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 29%
1.7%
15
Development
497 papers in training set
Top 3%
1.6%
16
Journal of Clinical Investigation
179 papers in training set
Top 3%
1.6%
17
JCI Insight
277 papers in training set
Top 5%
1.3%
18
EMBO Reports
263 papers in training set
Top 5%
1.3%
19
Cell Reports Medicine
153 papers in training set
Top 3%
1.3%
20
npj Regenerative Medicine
24 papers in training set
Top 0.5%
1.1%
21
iScience
1154 papers in training set
Top 28%
1.1%
22
Nature Cell Biology
118 papers in training set
Top 3%
1.1%
23
Blood Advances
62 papers in training set
Top 1.0%
1.0%
24
Nature Cardiovascular Research
33 papers in training set
Top 0.8%
0.8%
25
The EMBO Journal
309 papers in training set
Top 7%
0.8%
26
Communications Biology
993 papers in training set
Top 32%
0.8%
27
eLife
5828 papers in training set
Top 66%
0.8%
28
Cell Research
51 papers in training set
Top 2%
0.6%
29
Nature
645 papers in training set
Top 12%
0.6%
30
Molecular Therapy
81 papers in training set
Top 2%
0.6%